Business Update

Critical Therapeutics' new business strategy focuses on controlled-release and intravenous zileuton

Published in Physician Law Weekly, November 29th, 2006

Critical Therapeutics, Inc. (CRTX) announced a new business strategy to focus the company's resources on the commercialization of the twice daily, controlled-release formulation of zileuton (zileuton CR) for the chronic treatment of asthma and on clinical development of the intravenous formulation of zileuton (zileuton IV) for acute asthma.

As part of this initiative, Critical Therapeutics will significantly reduce net cash expenditures through lower spending on its U.S. specialty sales force, as well as on its research and development programs. In a separate release, the company announced that it has entered into definitive agreements with institutional investors for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2006-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry